European VitreoRetinal Society a certain philosophy

http://www.dailymotion.com/video/xo92d9 http://www.dailymotion.com/video/xo96f4 Francisco J. Ascaso, Laura Villén, Valentín Huerva, Javier Mateo, María A. Del Buey (Zaragoza, Spain) Advantages: Choroidal osteoma (CO), typically found in healthy young women, is a rare benign intraocular tumor composed of mature cancellous bone replacing the full thickness of the choroid. Vision loss in CO depends on tumor location, serous retinal...

Susan J. Wong, PhD (Albany, NY), Paul M. Beer, MD (Albany, NY) PURPOSE: Bevacizumab, a humanized monoclonal antibody targeting VEGF, is currently injected into vitreous humor to treat age-related macular degeneration. proliferative diabetic retinopathy and other conditions associatd with vascular leakage and angiogenesis. We developed a suspension phase microsphere immunoassay of free bevacizumab levels in ocular fluids and serum to enable...

Asheesh Tewari, MD (St. Louis, MO), Rajendra S. Apte, MD, PhD (St. Louis, MO)* PURPOSE: To examine outcomes of a group of previously treatment naïve patients treated with combined photodynamic therapy with verteporfin and intravitreal pegaptanib for choroidal neovascularization secondary to ARMD. METHODS: Retrospective review of ten eyes of ten consecutive patients with CNV secondary to ARMD. These patients had  not received  any prior...

http://www.evrs.eu/medias/2006/congress/Intravitreal-Bevacizumab-(Avastin)-Enhanced-Pegaptanib-(Macugen)-Therapy-for-Choroidal-Neovascularization-in-AMD:-An Avastin-Booster.swf Michael J. Tolentino, MD (Winter Haven, FL),* David M. Misch, MD (Winter Haven, FL), Adam S. Berger, MD (Winter Haven, FL), Suk Jin Moon, MD (Winter Haven, Fl) PURPOSE: The study purpose is to determine if bevacizumab combined with pegaptanib can harness the rapid...

Manjula Patel, MD (New York, NY),* Jordi Mones, MD (Barcelona, Spain), Anita Leys, PhD, MD (Leuven, Belgium), Gergana Zlateva, PhD (New York, NY),* Sonali N. Shah, BS Pharm, MPH (New York, NY)* PURPOSE: Patients with AMD are more likely to need help with daily activities, experience more emotional distress, and report a reduced quality of life than those without AMD. Pegaptanib sodium is the first pharmacological treatment for subfoveal...

Virgilio Morales-Canton, MD (Mexico City, Mexico), Maura Lucy Abraham Marin, MD (Mexico City, Mexico), Carlos Fernando Cortes Luna, MD (Bogota, Colombia), Lidia Griselda Alvarez-Rivera, MD (Mexico City, Mexico), Myriam L Hernandez-Rojas, (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico) PURPOSE: Evaluate efficacy and safety of intravitreal bevacizumab therapy for neovascular age-related macular degeneration...

Andreas Lipski, MD (Essen, Germany), Norbert Bornfeld (Essen, Germany), Mete Gök, Dr. (Essen, Germany), Bernhard Jurklies, Priv.-Doz. Dr. (Essen, Germany) PURPOSE: Electrophysiological and clinical follow-up of central retinal function in patients with minimally classic or occult SRNV in wet ARMD undergoing intravitreal therapy with Pegaptanib-Natrium (Macugen). METHODS: Eight patients with minimally classic and five patients with occult...

Peter K. Kaiser, MD (Cleveland, OH)* PURPOSE: The VeriTAS study is designed to evaluate the efficacy and safety of verteporfin PDT combined with either intravitreal triamcinolone acetonide or pegaptanib sodium to treat subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The 24-month randomized, double-masked VeriTAS study enrolled patients at 50 centers in the U.S. METHODS: Inclusion criteria:...

ThucAnh Thi Ho, MD (Chicago, IL), Pauline Townsend Merrill, MD (Chicago, IL) PURPOSE: To evaluate the role of combined intravitreal pegaptanib and photodynamic therapy with verteporfin (PDT) in the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We performed a retrospective review on 11 eyes of 11 patients treated with combined pegaptanib and PDT. Pre-treatment and...

Paul B. Griggs, MD (Seattle, WA), Richard C. Lee, BS (Seattle, WA) PURPOSE: To review the clinical results of sequential pegaptanib monotherapy following verteporfin photodynamic therapy for choroidal neovascularization. METHODS: Patients were identified in which pegaptanib therapy was initiated following initial treatment of choroidal neovascularization with verteporfin photodynamic therapy with or without adjuvant intravitreal...

http://www.evrs.eu/medias/2006/congress/Optical-Coherence-Tomography-Following-Pegaptanib-Therapy-in-Diabetics:-A-Bioanatomic-Study-of-DME.swf Mauro Goldbaum, MD (New York, NY),* David R. Guyer, MD (New York, NY),* Barrett Katz,MD (New York, NY)* PURPOSE: Preclincal and clinical data support a role for vascular endothelial growth factor (VEGF)165 in the pathogenesis of ocular neovascular diseases, suggesting that inhibiting the effects of...

http://www.evrs.eu/medias/2006/congress/Pegaptanib-Sodium-in-Diabetic-Retinopathy:-Improvements-in-Diabetic-Macular-Edema,-Retinal-Neovascularization,-and-Severity-of-Diabetic-Retinopathy.swf Victor Hugo Gonzalez, MD (Mcallen, TX) PURPOSE: Preclinical data indicate that pegaptanib, an aptamer targeting VEGF165, can reverse diabetesinduced blood-retinal barrier breakdown; clinical trials demonstrate pegaptanib’s efficacy in treating...

Lucian V. Del Priore, MD, PhD (New York, NY), Ankoor R. Shah, BS (New York, NY) PURPOSE: Multiple pharmacological treatments (photodynamic therapy [PDT], Macugen, Lucentis, and Anecortave Acetate [AA]) exist for exudative AMD; typically these treatments are compared to controls in clinical trials but not to one another. We have shown the rate of visual loss in untreated eyes is linear on a double reciprocal Lineweaver-Burke (LB) plot with...

http://www.evrs.eu/medias/2006/congress/Intravitreally-Injected-Anti-VEGF-Drugs-Exert-a-Biological-Effect-in-the-Fellow-Eye.swf Tongalp H. Tezel, MD (Louisville, KY), Charles C. Barr, MD (Louisville, KY), Henry J. Kaplan, MD (Louisville, KY) PURPOSE: To determine whether the intravitreal injection of anti-VEGF drugs (Kenalog, Macugen, Avastin) exert any biological effect in the fellow eyes of patients with bilateral exudative...

http://www.evrs.eu/medias/2006/congress/The-Value-and-Cost-effectiveness-of-Interventions-for-Subfoveal,-Neovascular,-Age-related-Macular-Degeneration-(ARMD).swf Melissa M. Brown, MD, MN, MBA (Flourtown, PA),* Gary C. Brown, MD, MBA (Wyndmoor, PA)* PURPOSE: To assess the value of interventions utilized for the treatment of subfoveal, neovascular, agerelated macular degeneration (ARMD) employing evidencebased data from clinical trials...

Gregory R. Blaha, MD, PhD (Peabody, MA), Jeffrey L. Marx, MD (Peabody, MA)* PURPOSE: To report our experience with combination low-fluence PDT. METHODS: An IRB-approved, retrospective chart review of all patients receiving low-fluence (50% standard) PDT (LFPDT) at our institution was performed. RESULTS: Twenty five eyes of 24 patients received LFPDT. Two eyes did not receive combination therapy, two received Macugen (Pegaptanib,...

Chris Bergstrom, MD (Atlanta, GA), G. Baker Hubbard, MD (Atlanta, GA) PURPOSE: To evaluate pegaptanib therapy for iris neovascularization in patients with proliferative diabetic retinopathy and vitreous hemorrhage who have already received laser ablative therapy. METHODS: This is an interventional noncomparitive series of patients with iris neovascularization secondary to proliferative diabetic retinopathy treated with injections of...

John A. Wells, MD, FACS (Columbia, SC),* PURPOSE: Vascular endothelial growth factor (VEGF) both promotes angiogenesis and enhances vascular permeability. VEGF levels rise following retinal vein occlusion. Selective VEGF blockade has been effective in treating diabetic macular edema. The current trial examined whether this approach was effective in treating macular edema that follows CRVO. METHODS: A randomized, multicenter, double-masked,...

http://www.evrs.eu/medias/2005/congress/VEGF-Inhibition-Study-in-Ocular-Neovascularization-(Vision):-Outcomes-from-the-Phase-II-III-Macugen-Pivitol-Trials.swf Thomas R. Friberg and the Macugen Study Group Purpose: To evaluate the safety and effectiveness of Macugen in the treatment of exudative AMD. Methods: Two phase II/III randomized, double masked, multicentered trials were conducted to study the effect of pegatanib sodium (Macugen)...